Table 2.
Variation in Coverage Policies Across Indication, Evidence Base, Use and Technology Platform
| Cover High Riska | Cover Average Riska | Assess Analytical Validity | Assess Clinical Validity | Assess Clinical Utility | Cover Sex Chromosome Aneuploidy or Microdeletions | Include NGS and Array Platforms | Genetic Counseling Recommended | |
|---|---|---|---|---|---|---|---|---|
| Payer 1 | + | + | + | + | − | − | + | + |
| Payer 2 | + | − | + | + | + | − | + | + |
| Payer 3 | + | − | − | + | − | − | + | + |
| Payer 4 | + | + | + | + | + | − | + | + |
| Payer 5 | + | − | − | + | + | − | + | + |
| Payer 6 | + | − | − | − | − | − | + | − |
| Payer 7 | + | − | + | + | − | − | + | + |
| Payer 8 | + | − | − | + | − | − | + | − |
| Payer 9 | + | + | + | + | + | − | + | + |
| Payer 10 | + | + | + | + | + | − | + | + |
| Payer 11 | + | + | + | + | + | − | + | + |
| Payer 12 | + | + | + | + | + | − | + | + |
| Payer 13 | + | + | − | + | − | − | + | − |
| Payer 14 | + | − | + | + | + | − | + | − |
| Payer 15 | + | − | + | + | + | − | + | − |
| Payer 16 | + | − | − | + | + | + | + | + |
| Payer 17 | + | + | − | + | + | − | + | − |
| Payer 18 | + | − | − | + | − | − | + | + |
| Payer 19 | + | − | − | + | − | − | + | − |
| Total | 19 | 8 | 10 | 18 | 11 | 1 | 19 | 12 |
a
for T21, T18, T13 in singleton pregnancies